Artigo de periodico

Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial (2022)

• Authors:
  • Ramacciotti, Eduardo
  • Agati, Leandro Barile
  • Calderaro, Daniela
  • Aguiar, Valéria Cristina Resende
  • Spyropoulos, Alex C
  • Oliveira, Caroline Candida Carvalho de
  • Santos, Jessica Lins dos
  • Volpiani, Giuliano Giova
  • Sobreira, Marcone Lima - Universidade Estadual Paulista Júlio de Mesquita Filho (UNESP)
  • Joviliano, Edwaldo Edner
  • Bohatch Júnior, Milton Sérgio
  • Fonseca, Benedito Antonio Lopes da
  • Ribeiro, Maurício Serra
  • Dusilek, Cesar
  • Itinose, Kenji
  • Sanches, Suzanna Maria Viana
  • Ramos, Karine de Almeida Araujo
  • Moraes, Nara Franzin de
  • Tierno, Paulo Fernando Guimarães Morando Marzocchi
  • Oliveira, André Luiz Menezes de
  • Tachibana, Adriano - Hospital Israelita Albert Einstein (HIAE)
  • Chate, Rodrigo Caruso - Hospital Israelita Albert Einstein (HIAE)
  • Santos, Marcus Vinícius Barbosa
  • Cavalcante, Bruno Bezerra de Menezes
  • Moreira, Ricardo Cesar Rocha
  • Chiann, Chang
  • Tafur, Alfonso
  • Fareed, Jawed
  • Lopes, Renato D
  • MICHELLE investigators
• USP affiliated authors: JOVILIANO, EDWALDO EDNER - FMRP ; FONSECA, BENEDITO ANTONIO LOPES DA - FMRP ; RIBEIRO, MAURÍCIO SERRA - FMRP ; CHIANN, CHANG - IME ; BOHATCH JÚNIOR, MILTON SÉRGIO - FMRP
• Unidades: FMRP; IME
• DOI: 10.1016/S0140-6736(21)02392-8
• Subjects: COVID-19; TROMBOCITOPENIA; BIOESTATÍSTICA
• Agências de fomento:
  • Financiamento Bayer
• Language: Inglês
• Imprenta:
  • Publisher place: Amsterdam
  • Date published: 2022
• Source:
  • Título do periódico: The Lancet
  • ISSN: 0140-6736
  • Volume/Número/Paginação/Ano: v. 399, n. 10319, p. 50-59, 2022

Informações sobre o DOI: 10.1016/S0140-6736(21)02392-8 (Fonte: oaDOI API)
• Este periódico é de assinatura
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: bronze

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  RAMACCIOTTI, Eduardo et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, v. 399, n. 10319, p. 50-59, 2022Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(21)02392-8. Acesso em: 27 abr. 2024.

• APA

  Ramacciotti, E., Agati, L. B., Calderaro, D., Aguiar, V. C. R., Spyropoulos, A. C., Oliveira, C. C. C. de, et al. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. The Lancet, 399( 10319), 50-59. doi:10.1016/S0140-6736(21)02392-8

• NLM

  Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8

• Vancouver

  Ramacciotti E, Agati LB, Calderaro D, Aguiar VCR, Spyropoulos AC, Oliveira CCC de, Santos JL dos, Volpiani GG, Sobreira ML, Joviliano EE, Bohatch Júnior MS, Fonseca BAL da, Ribeiro MS, Dusilek C, Itinose K, Sanches SMV, Ramos K de AA, Moraes NF de, Tierno PFGMM, Oliveira ALM de, Tachibana A, Chate RC, Santos MVB, Cavalcante BB de M, Moreira RCR, Chiann C, Tafur A, Fareed J, Lopes RD, MICHELLE investigators. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial [Internet]. The Lancet. 2022 ; 399( 10319): 50-59.[citado 2024 abr. 27 ] Available from: https://doi.org/10.1016/S0140-6736(21)02392-8

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• MicroRNAs and current concepts on the pathogenesis of abdominal aortic aneurysm
• Endovascular treatment of left internal thoracic artery aneurysm
• Endovascular repair of a ruptured abdominal aortic aneurysm after endovascular aneurysm repair due type IB endoleak associated with a late fistula between the abdominal aorta and a retroaortic left renal vein
• Inpatient consultations with the vascular and endovascular surgery team at an academic tertiary hospital
• Endovascular approach to transplant renal artery stenosis
• Aortogastric fistula due to a penetrating atherosclerotic aortic ulcer
• Carbon-coated stent and the role of the kallikrein-kinin system in peripheral angioplasty
• Cirurgia aberta e endovascular no tratamento de aneurisma de artéria poplítea: experiência de cinco anos do HCRP-FMRP
• Medically ill hospitalized patients for COVID-19 thrombosis extended prophylaxis with rivaroxaban therapy: rationale and design of the MICHELLE trial
• Energy performance and greenhouse gas emissions of kelp cultivation for biogas and fertilizer recovery in Sweden